AAA today presented new safety and efficacy data from the pivotal Phase 3 NETTER-1 study investigating the treatment of Lutathera (177-Lu-Dotatate) in patients with inoperable, progressive, somatostatin receptor positive midgut neuroendocrine tumors (midgut NETs) at the 2016 Gastrointestinal Cancer Symposium ASCO GI in San Francisco, California.
The results were presented today in oral session by key study investigator Prof. J. R. Strosberg and during the official ASCO GI presscast on Tuesday 19 January 2016. The abstract presented was abstract 194 “NETTER-1 phase III: Progression-free survival, radiographic response, and preliminary overall survival results in patients with midgut neuroendocrine tumors treated with 177-Lu-Dotatate.»
A webcast of the presscast with the NETTER-1 presentation is available online at: Gastrointestinal Cancers Symposium Media Resource Center